

Bronchopulmonary Dysplasia Therapeutic Pipeline Market Review, H2 2016

Bronchopulmonary Dysplasia Treatment Pipeline Review H2 2016

PUNE, INDIA, October 10, 2016

/EINPresswire.com/ --

[Bronchopulmonary Dysplasia](#) - Pipeline Review, H2 2016

The report provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/649775-bronchopulmonary-dysplasia-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bronchopulmonary



Dysplasia

- The report reviews pipeline therapeutics for Bronchopulmonary Dysplasia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bronchopulmonary Dysplasia therapeutics and enlists all their major and minor projects
- The report assesses Bronchopulmonary Dysplasia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bronchopulmonary Dysplasia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Buy 1-User PDF@ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=649775

Table of Content

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Bronchopulmonary Dysplasia Overview	7
Therapeutics Development	8
Pipeline Products for Bronchopulmonary Dysplasia - Overview	8
Bronchopulmonary Dysplasia - Therapeutics under Development by Companies	9
Bronchopulmonary Dysplasia - Pipeline Products Glance	10
Late Stage Products	10
Clinical Stage Products	11
Early Stage Products	12
Bronchopulmonary Dysplasia - Products under Development by Companies	13
Bronchopulmonary Dysplasia - Companies Involved in Therapeutics Development	14
Airway Therapeutics LLC	14
Chiesi Farmaceutici SpA	15
Insmmed Incorporated	16
MediPost Co., Ltd.	17
Meridigen Biotech Co., Ltd.	18
Syntrix Biosystems, Inc.	19
Therabron Therapeutics, Inc.	20
Bronchopulmonary Dysplasia - Therapeutics Assessment	21
Assessment by Monotherapy Products	21
Assessment by Target	22
Assessment by Mechanism of Action	24
Assessment by Route of Administration	26
Assessment by Molecule Type	28
Drug Profiles	30
AT-100 - Drug Profile	30
Product Description	30
Mechanism Of Action	30
R&D Progress	30
budesonide - Drug Profile	31
Product Description	31
Mechanism Of Action	31
R&D Progress	31
CG-100 - Drug Profile	32
Product Description	32

Access Report @ <https://www.wiseguyreports.com/reports/649775-bronchopulmonary-dysplasia-pipeline-review-h2-2016>

Follow Us:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/348680385>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.